292 related articles for article (PubMed ID: 29343575)
1. High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.
Ita S; Hill AK; Lam EC; Dufort FJ; Yang X; Newman R; Leviyang S; Fofana IB; Johnson WE
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343575
[TBL] [Abstract][Full Text] [Related]
2. Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.
Rudensey LM; Kimata JT; Long EM; Chackerian B; Overbaugh J
J Virol; 1998 Jan; 72(1):209-17. PubMed ID: 9420217
[TBL] [Abstract][Full Text] [Related]
3. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
Chackerian B; Rudensey LM; Overbaugh J
J Virol; 1997 Oct; 71(10):7719-27. PubMed ID: 9311856
[TBL] [Abstract][Full Text] [Related]
4. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
[TBL] [Abstract][Full Text] [Related]
5. Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.
Zhou M; Humbert M; Mukhtar MM; Scinto HB; Vyas HK; Lakhashe SK; Byrareddy SN; Maurer G; Thorat S; Owuor J; Lai Z; Chen Y; Griffiths A; Chenine AL; Gumber S; Villinger F; Montefiori D; Ruprecht RM
J Virol; 2019 May; 93(9):. PubMed ID: 30760566
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques.
Mitchell WM; Torres J; Johnson PR; Hirsch V; Yilma T; Gardner MB; Robinson WE
AIDS; 1995 Jan; 9(1):27-34. PubMed ID: 7893438
[TBL] [Abstract][Full Text] [Related]
7. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.
Jurkiewicz E; Hunsmann G; Schäffner J; Nisslein T; Lüke W; Petry H
J Virol; 1997 Dec; 71(12):9475-81. PubMed ID: 9371609
[TBL] [Abstract][Full Text] [Related]
8. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
Burns DP; Collignon C; Desrosiers RC
J Virol; 1993 Jul; 67(7):4104-13. PubMed ID: 8510218
[TBL] [Abstract][Full Text] [Related]
9. Antigenic variation of SIV: mutations in V4 alter the neutralization profile.
Kinsey NE; Anderson MG; Unangst TJ; Joag SV; Narayan O; Zink MC; Clements JE
Virology; 1996 Jul; 221(1):14-21. PubMed ID: 8661410
[TBL] [Abstract][Full Text] [Related]
10. Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses.
Marthas ML; Lu D; Penedo MC; Hendrickx AG; Miller CJ
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1455-66. PubMed ID: 11679158
[TBL] [Abstract][Full Text] [Related]
11. Similar abnormalities of idiotype and immunoglobulin light chain expression and of cell-mediated cytotoxicity in HIV-infected humans and simian immunodeficiency virus (SIV)-infected rhesus macaques.
Grant MD; Whaley MD; Mayne A; Hoffmann GW; Ansari AA
Immunol Cell Biol; 1996 Feb; 74(1):38-44. PubMed ID: 8934652
[TBL] [Abstract][Full Text] [Related]
12. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
[TBL] [Abstract][Full Text] [Related]
13. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
[TBL] [Abstract][Full Text] [Related]
14. Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS.
Kodama T; Mori K; Kawahara T; Ringler DJ; Desrosiers RC
J Virol; 1993 Nov; 67(11):6522-34. PubMed ID: 8411355
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.
Petry H; Pekrun K; Hunsmann G; Jurkiewicz E; Lüke W
J Virol; 2000 Dec; 74(23):11145-52. PubMed ID: 11070011
[TBL] [Abstract][Full Text] [Related]
16. Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques.
McCormick-Davis C; Zhao LJ; Mukherjee S; Leung K; Sheffer D; Joag SV; Narayan O; Stephens EB
Virology; 1998 Sep; 248(2):275-83. PubMed ID: 9721236
[TBL] [Abstract][Full Text] [Related]
17. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.
Burns DP; Desrosiers RC
J Virol; 1991 Apr; 65(4):1843-54. PubMed ID: 2002545
[TBL] [Abstract][Full Text] [Related]
18. Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques.
Greenier JL; Miller CJ; Lu D; Dailey PJ; Lü FX; Kunstman KJ; Wolinsky SM; Marthas ML
J Virol; 2001 Apr; 75(8):3753-65. PubMed ID: 11264364
[TBL] [Abstract][Full Text] [Related]
19. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.
Burns DP; Desrosiers RC
Curr Top Microbiol Immunol; 1994; 188():185-219. PubMed ID: 7523031
[TBL] [Abstract][Full Text] [Related]
20. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.
Haigwood NL; Watson A; Sutton WF; McClure J; Lewis A; Ranchalis J; Travis B; Voss G; Letvin NL; Hu SL; Hirsch VM; Johnson PR
Immunol Lett; 1996 Jun; 51(1-2):107-14. PubMed ID: 8811353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
